Table 1 Patient characteristics
All Cases | No fractures | Fractures | P value | |
|---|---|---|---|---|
n = 2112 | n = 2043 | n = 69 | ||
Sex (male, %) | 64.9 | 65.6 | 36.8 | < 0.001 |
Age (years) | 76.5 ± 7.1 | 76.4 ± 7.1 | 79.7 ± 7.6 | 0.002 |
BMI (kg/m2) | 23.1 ± 4.1 | 23.1 ± 4.1 | 22.3 ± 5.0 | 0.9 |
HbA1c (%) | 7.1 ± 1.2 | 7.1 ± 1.2 | 6.8 ± 1.4 | 0.92 |
eGFR (mL/min/1.73m2) | 54.5 ± 22.1 | 54.3 ± 22.1 | 62.1 ± 23.9 | 0.02 |
Patients with fractures, n (%) | 69 (3.3%) | 0 (0) | 69 (100) | < 0.001 |
Number of drugs being administered at the time of hospitalization | 7.7 ± 3.8 | 7.7 ± 3.8 | 7.7 ± 3.3 | 0.52 |
Patients not using hypoglycemic agent, n (%) | 700 (33.1) | 674 (33.0) | 26 (36.8) | 0.62 |
Glinides, n (%) | 0 | 0 | 0 | – |
SGLT2 inhibitors, n (%) | 8 (0.4) | 8 (0.4) | 0 | 0.7 |
TZD, n (%) | 148 (7.0) | 137 (6.7) | 11 (15.9) | 0.03 |
αGI, n (%) | 200 (9.5) | 194 (9.5) | 6 (8.7) | 0.74 |
BG, n (%) | 407 (19.3) | 398 (19.5) | 9 (13.0) | 0.17 |
SU, n (%) | 542 (25.7) | 527 (25.8) | 15 (21.7) | 0.3 |
DPP-4 inhibitors, n (%) | 904 (42.8) | 877 (42.9) | 27 (39.1) | 0.45 |
GLP-1 receptor agonists, n (%) | 39 (1.8) | 36 (1.8) | 3 (4.3) | 0.11 |
Insulin, n (%) | 440 (20.8) | 425 (20.8) | 15 (21.7) | 0.66 |